awmsg logo



rufinamide (Inovelon®)


Reference No. 991


Appraisal information

rufinamide (Inovelon®) 40 mg/ml oral suspension


Company: Eisai Ltd
BNF category: Central nervous system
NMG meeting date: 08/05/2019
AWMSG meeting date: 19/06/2019
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Adjunctive therapy in the treatment of seizures associated with Lennox‑Gastaut syndrome in patients 1 year of age to less than 4 years of age
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download